Merestinib
Appearance
![]() | |
Clinical data | |
---|---|
Routes of administration | PO |
ATC code |
|
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.233.673 |
Chemical and physical data | |
Formula | C30H22F2N6O3 |
Molar mass | 552.542 g·mol−1 |
3D model (JSmol) | |
| |
|
Merestinib (LY2801653) is an experimental cancer drug in development by Eli Lilly. It is a small molecule inhibitor of MET and several other receptor tyrosine kinases such as MST1R, FLT3, AXL, MERTK, TEK, ROS1, NTRK1/2/3, and DDR1/2.
Meristinib is part of a phase II clinical trial for advanced billiary tract cancer. The study is expected to be complete in April 2018.[1] Phase II clinical trials for non-small cell lung cancer and solid tumors began in November 2016.[2]
References
- ^ Clinical trial number NCT02711553 for "A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer" at ClinicalTrials.gov
- ^ "Merestinib - Eli Lilly". AdisInsight. Springer Nature Switzerland AG.